13 August 2008: NorDiag ASA invites to a breakfast presentation of the second quarter and first half year 2008 results on August 21 2008 at 8:30am at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo.

Please confirm your participation to elin.flo@nordiag.com or by calling +47 55 54 39 60. Shareholders who wish to receive the quarterly report by mail are requested to send an email regarding this to the same email address.

Representatives from the Company will be CEO Mårten Wigstøl and CFO Tone Kvåle.

The second quarter and first half year report and the presentation will be published on NorDiag`s homepage www.nordiag.com

Contact:
CFO Tone Kvåle, phone +47 915 19576.

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the Notice on OSE's Newsweb here

Read the Notice in Norwegian here